---
title: Predict Parkinson in essential tremor
nct_id: NCT07428447
status: RECRUITING
sponsor: CND Life Sciences
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07428447"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07428447"
last_fetched: "2026-05-10T14:07:42.316Z"
source: "Parkinson's Pathways (curated)"
---
# Predict Parkinson in essential tremor

**Goal (in five words):** Predict Parkinson in essential tremor

**Official Title:** Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease

**Trial ID:** [NCT07428447](https://clinicaltrials.gov/study/NCT07428447)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** CND Life Sciences
- **Target Enrollment:** 300 participants
- **Start Date:** 2026-02-18
- **Completion Date:** 2027-02
- **Conditions:** Essential Tremor, Movement Disorders, Essential Tremor, Essential Tremor-plus

## Summary For Families

The goal is to see whether phosphorylated alpha-synuclein, a Parkinson's-related protein, shows up in the skin of people with essential tremor or ET-plus and can predict who is more likely to go on to develop Parkinson's disease. The approach is a biomarker test using small skin biopsies to look for phosphorylated alpha-synuclein, which reflects the abnormal protein clumps seen in Parkinson's; this is not a treatment and it does not affect or interact with levodopa. The study is looking for adults 50 to 85 years old with ET or ET-plus by the 2018 MDS criteria who can consent and complete procedures, and it excludes people with other neurodegenerative disorders, abnormal DaTscan, active bleeding or wound-healing risks, current use of carbidopa-levodopa, or anticoagulant/dual antiplatelet therapy.

## Eligibility

- **Minimum age:** 50 Years
- **Maximum age:** 85 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Age 50-85 years old
* Diagnosis of ET as defined by the 2018 MDS Task force paper "1) isolated tremor syndrome of bilateral upper limb action tremor 2) at least 3 years' duration 3) with or without tremor in other locations (e.g., head, voice, or lower limbs) 4) absence of other neurological signs, such as dystonia, ataxia, or parkinsonism." OR
* Diagnosis of ET-Plus as stated by the 2018 MDS Task force paper, "Tremor with the characteristics of ET and additional neurological signs of uncertain significance such as impaired tandem gait, questionable dystonic posturing, memory impairment, or other mild neurologic signs of unknown significance that do not suffice to make an additional syndrome classification or diagnosis. ET with tremor at rest should be classified here."
* Willing to participate in all study procedures
* Able and willing to provide written informed consent

Exclusion Criteria:

* Under age 50, Over age 85
* Clinical evidence of severe peripheral vascular disease
* Clinically active coronary artery or cerebrovascular disease
* Participant is currently on anticoagulant or dual anti-platelet therapy
* Alcoholism
* Allergic reaction to local anesthesia
* History of or increased risk for impaired wound healing, scarring, or keloid formation
* Diagnosis of ET or ET-Plus that is clinically determined to likely be secondary to brain injury or vascular compromise
* History of other neurodegenerative disorder or evidence of neurological co-pathology
* Abnormal DaTscan
* Participant is currently receiving treatment with carbidopa-levodopa for PD
* Isolated focal tremors (head, voice)
* Task-specific tremor (e.g., primary writing tremor)
* Position-specific tremors that does not otherwise meet clinical diagnostic criteria for ET
* Sudden onset and step-wise deterioration
```

## Locations (1)

- CND Clinical Research Center, Scottsdale, Arizona, United States _(33.5092, -111.8990)_
  - Jeannie Director of Clinical Research — (CONTACT) — 480-434-6446 — ClinicalResearch@cndlifesciences.com

## Central Contacts

- Jeannie Director of Clinical Research — (CONTACT) — 480-434-6446 — ClinicalResearch@cndlifesciences.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT07428447*  
*HTML version: https://parkinsonspathways.com/trial/NCT07428447*  
*Source data: https://clinicaltrials.gov/study/NCT07428447*